Details of the Drug Combinations

General Information of This Drug (ID: DMO8PT9)

• Drug Name: MLN8237 (DMO8PT9)
• Synonyms: Alisertib

Indication

Solid tumour/cancer; ICD 11: 2A00-2F9Z; Status: Phase 3 [1]; Small-cell lung cancer; ICD 11: 2C25.Y; Status: Phase 2 [2]

• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

12 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Fostamatinib + MLN8237	DC0XK8K	Fostamatinib	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
MLN8237 + Ruxolitinib	DCB3YZD	Ruxolitinib	T-cell leukemia/lymphoma (Cell Line: ED-40515)	[3]
MLN8237 + JQ1	DCSXFFT	JQ1	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
MLN8237 + Ym155	DCZQ7BN	Ym155	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
MLN8237 + Marizomib	DC4UR9R	Marizomib	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
MLN8237 + SNS-032	DCWFWE1	SNS-032	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
MLN8237 + Mifepristone	DCO58K2	Mifepristone	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
MLN8237 + Tamoxifen	DCDYJ8B	Tamoxifen	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
MLN8237 + IMD-0354	DCERGI0	IMD-0354	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
MLN8237 + BMS-754807	DC819RJ	BMS-754807	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
MLN8237 + Vinpocetine	DCY84XT	Vinpocetine	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
RTB101 + MLN8237	DCWYMQG	RTB101	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]

13 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Docetaxel + MLN8237	DCSS5OL	Docetaxel	Advanced Solid Tumors	[4]
Esomeprazole + MLN8237	DCWIVAW	Esomeprazole	Solid Tumors	[5]
Idarubicin + MLN8237	DCK8NZ3	Idarubicin	Acute Myelogenous Leukemia	[6]
Itraconazole + MLN8237	DCOHHDZ	Itraconazole	Advanced Solid Tumors	[7]
MLN2480 + MLN8237	DC3L73P	MLN2480	Advanced Nonhematologic Malignancies	[8]
MLN8237 + Sapanisertib	DC12USM	Sapanisertib	Malignant Neoplasms of Digestive Organs	[9]
MLN8237 + Osimertinib	DC20ZO4	Osimertinib	Lung Cancer Metastatic	[10]
Pazopanib + MLN8237	DCL2I32	Pazopanib	Malignant Neoplasm of Breast	[11]
Rifampicin + MLN8237	DCASU1Q	Rifampicin	Solid Tumors	[5]
Temozolomide + MLN8237	DC7ILW1	Temozolomide	Neuroblastoma	[12]
Idarubicin + MLN8237	DC9J2VB	Idarubicin	Acute Myeloid Leukemia	[13]
Paclitaxel + MLN8237	DC21IJH	Paclitaxel	Bladder Cancer	[14]
Paclitaxel + MLN8237	DCFHV22	Paclitaxel	Breast Cancer	[15]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7790).
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [4] ClinicalTrials.gov (NCT01094288) A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen
• [5] ClinicalTrials.gov (NCT01844583) Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib
• [6] ClinicalTrials.gov (NCT01779843) Alisertib for Acute Myeloid Leukemia
• [7] ClinicalTrials.gov (NCT02259010) A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
• [8] ClinicalTrials.gov (NCT02327169) A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies
• [9] ClinicalTrials.gov (NCT02812056) Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies
• [10] ClinicalTrials.gov (NCT04085315) Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
• [11] ClinicalTrials.gov (NCT01639911) Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors
• [12] ClinicalTrials.gov (NCT01601535) Study of MLN8237 in Combination With Irinotecan and Temozolomide
• [13] ClinicalTrials.gov (NCT02560025) Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML
• [14] ClinicalTrials.gov (NCT02109328) Alisertib in Chemotherapy-pretreated Urothelial Cancer
• [15] ClinicalTrials.gov (NCT02187991) Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer